Journal of Clinical Oncology, Vol 16, 1094-1098, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix

M Morris, KR Brader, C Levenback, TW Burke, EN Atkinson, WR Scott and DM Gershenson
Department of Gynecologic Oncology, University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA. morris@ovp.mdacc.tmc.edu

PURPOSE: To evaluate the efficacy and toxicity of intravenous vinorelbine as single-agent chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the cervix. PATIENTS AND METHODS: Between August 1993 and July 1995, 35 patients with advanced or recurrent squamous cell carcinoma of the cervix were entered onto this study. Patients had received no prior therapeutic chemotherapy. The initial dose of vinorelbine 30 mg/m2 was administered as a weekly intravenous infusion. Subsequent doses were unchanged, reduced, escalated, or omitted according to observed toxicity. Patients were evaluated for response and toxicity using standard Gynecologic Oncology Group (GOG) and World Health Organization criteria, respectively. RESULTS: Thirty-three of 35 patients were assessable for response and 35 of 35 for toxicity. The overall response rate was 18% (one complete response [CR], five partial responses [PR]). The mean response duration was 5.2 months and the median survival from treatment for all patients was 11.0 months. The major toxicity was leukopenia, with 61% of patients who had grade 3 or 4. Gastrointestinal and neurotoxicity were infrequent and mild. CONCLUSION: Vinorelbine has moderate activity in advanced or recurrent squamous cell carcinoma of the cervix. Further studies of combination regimens with this agent are justified in this patient population.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. J. Long III Management of Metastatic Cervical Cancer: Review of the Literature J. Clin. Oncol., July 10, 2007; 25(20): 2966 - 2974. [Abstract] [Full Text] [PDF]

				I. van Luijk, C Coens, M. van der Burg, A Kobierska, M Namer, C Lhomme, P Zola, G Zanetta, J. Vermorken, and For the Gynecological Cancer Group of the European Phase II study of bleomycin, vindesine, mitomycin C and cisplatin (BEMP) in recurrent or disseminated squamous cell carcinoma of the uterine cervix Ann. Onc., February 1, 2007; 18(2): 275 - 281. [Abstract] [Full Text] [PDF]

				M. Morris, J. A. Blessing, B. J. Monk, R. McGehee, and D. H. Moore Phase II Study of Cisplatin and Vinorelbine in Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study J. Clin. Oncol., August 15, 2004; 22(16): 3340 - 3344. [Abstract] [Full Text] [PDF]

				D. H. Moore, J. A. Blessing, R. P. McQuellon, H. T. Thaler, D. Cella, J. Benda, D. S. Miller, G. Olt, S. King, J. F. Boggess, et al. Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study J. Clin. Oncol., August 1, 2004; 22(15): 3113 - 3119. [Abstract] [Full Text] [PDF]

				P. G. Rose Combined-Modality Therapy of Locally Advanced Cervical Cancer J. Clin. Oncol., May 15, 2003; 21(90100): 211s - 217. [Abstract] [Full Text] [PDF]

				M. Friedlander and M. Grogan Guidelines for the Treatment of Recurrent and Metastatic Cervical Cancer Oncologist, August 1, 2002; 7(4): 342 - 347. [Abstract] [Full Text] [PDF]

				C. Lhomme, P. Fumoleau, P. Fargeot, Y. Krakowski, V. Dieras, J. Chauvergne, P. Vennin, P. Rebattu, H. Roche, J.-L. Misset, et al. Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group Phase II Trial of First-Line Irinotecan in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Cervix J. Clin. Oncol., October 1, 1999; 17(10): 3136 - 3142. [Abstract] [Full Text] [PDF]

				S. Pignata, G. Silvestro, E. Ferrari, L. Selvaggi, F. Perrone, A. Maffeo, P. Frezza, G. Di Vagno, G. Casella, P. Ricchi, et al. Phase II Study of Cisplatin and Vinorelbine as First-Line Chemotherapy in Patients With Carcinoma of the Uterine Cervix J. Clin. Oncol., March 1, 1999; 17(3): 756 - 756. [Abstract] [Full Text] [PDF]

				C. A. Papadimitriou, K. Sarris, L. A. Moulopoulos, G. Fountzilas, A. Anagnostopoulos, Z. Voulgaris, D. Gika, N. Giannakoulis, E. Diakomanolis, and M. A. Dimopoulos Phase II Trial of Paclitaxel and Cisplatin in Metastatic and Recurrent Carcinoma of the Uterine Cervix J. Clin. Oncol., March 1, 1999; 17(3): 761 - 761. [Abstract] [Full Text] [PDF]